Blueprint Medicines BPMC
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Blueprint Medicines (BPMC) Business Model and Operations Summary
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Key Insights
Blueprint Medicines (BPMC) Core Market Data and Business Metrics
Latest Closing Price
$85.94Market Cap
$5.37 BillionPrice-Earnings Ratio
-80.32Total Outstanding Shares
62.62 Million SharesTotal Employees
655Dividend
No dividendIPO Date
April 30, 2015SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
45 Sidney Street, Cambridge, MA, 02139
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-192.59 Million |
| Net Cash Flow From Investing Activities, Continuing | $-47.50 Million |
| Net Cash Flow From Financing Activities, Continuing | $273.11 Million |
| Net Cash Flow From Financing Activities | $273.11 Million |
| Net Cash Flow | $33.02 Million |
| Net Cash Flow From Investing Activities | $-47.50 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit | $1.23 Million |
| Cost Of Revenue | $20.16 Million |
| Income/Loss From Continuing Operations Before Tax | $-65.86 Million |
| Diluted Earnings Per Share | $-1.07 |
| Basic Average Shares | $62.86 Million |
| Costs And Expenses | $720.87 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $-56,000 |
| Other Comprehensive Income/Loss | $-56,000 |
| Comprehensive Income/Loss | $-67.14 Million |
| Comprehensive Income/Loss Attributable To Parent | $-67.14 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $298.67 Million |
| Other Non-current Assets | $400.54 Million |
| Noncurrent Assets | $437.13 Million |
| Current Liabilities | $260.80 Million |
| Fixed Assets | $36.59 Million |
| Inventory | $13.61 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||